Register today for your certification!

Tachycardia Practice Test

Tachycardia is defined as: An arrhytmia with a rate greater than 150/min An arrhytmia with a rate greater than 100/min Any rhythm disorder with a heart rate less than 60/min An organized rhythm without a pulse Tachycardia is defined as an arrhythmia with a rate greater than 100/min AHA Advanced Cardiovascular Life Support Provider Manual, p. 130 Synchronized cardioversion is recommended for:: Monomorphic VT in a stable patient Pulseless rhythms Unstable SVT Polymorphic VT Synchronized shocks are recommended for patients with:
  • Unstable SVT
  • Unstable atrial fibrillation
  • Unstable atrial flutter
  • Unstable regular monomorphic tachycardia with a pulse
AHA Advanced Cardiovascular Life Support Provider Manual, p. 137
What is the correct energy dose for unstable atrial fibrillation when delivering monophasic synchronized shocks? 50 to 100 J 100 J Treat with high-energy shocks (defibrillation doses) 200 J The correct energy dose for unstable atrial fibrillation when delivering monophasic synchronized shocks is 200 J AHA Advanced Cardiovascular Life Support Provider Manual, p. 138 AV nodal blocking agents should be avoided in: Patients with a regular SVT Patients with a regular VT Patients with an irregular wide-complex tachycardia All of the above Avoid AV nodal blocking agents such as adenosine, calcium channel blockers, digoxin, and possible betat-blockers in patients with pre-excitation atrial fibrillation, because these drugs may cause a paradoxical increase in the ventricular response AHA Advanced Cardiovascular Life Support Provider Manual, p. 142 Which drug is the preferred intervention for terminating narrow-complex tachycardias that are symptomatic (but stable) and supraventricular in origin (SVT)? Epinephrine Amiodarone Atropine Adenosine Vagal maneuvers and Adenosine are the preferred intervention for terminating narrow-complex tachycardias that are symptomatic (but stable) and supraventricular in origin (SVT). AHA Advanced Cardiovascular Life Support Provider Manual, p. 142-143 Adenosine should not be given to: Patients with asthma Pregnant women Patients with SVT Patients with a narrow QRS with regular rhythm Adenosine may cause bronchospasm; therefore, adenosine should generally not be given to patients with asthma or chronic obstructive pulmonary disease. AHA Advanced Cardiovascular Life Support Provider Manual, p. 143 If SVT does not respond to vagal maneuvers, how much adenosine do you give: 20mL rapid IV push 12 mg rapid IV push 6 mg IV push over 10 seconds 6mg rapid IV push over 1 second Give adenosine 6 mg as a rapid IV push in a large (eg, antecubital) vein over 1 second. Follow with a 20 mL saline flush and elevate the arm immediately. AHA Advanced Cardiovascular Life Support Provider Manual, p. 143 Which of the following statements is not true? Sinus tachycardia is a heart rate that is greater than 100/min and is generated by sinus node discharge Sinus tachycardia is caused by cardiac conditions In sinus tachycardia, the goal is to identify and treat the underlying systemic cause. Cardioversion is contraindicated in Sinus Tachycardia Sinus tachycardia is caused by external influences on the heart. These are systemic conditions, not cardiac conditions. AHA Advanced Cardiovascular Life Support Provider Manual, p. 131, 134 Vagal maneuvers alone will terminate about what percentage of SVTs? 25% 90% 75% 50% Vagal maneuvers alone (Valsalva maneuver or carotid sinus massage) will terminate about 25% of SVTs. Adenosine is required for the remainder. AHA Advanced Cardiovascular Life Support Provider Manual, p. 143 End points for the administration of procainamide include: Hypotension Duration of QRS increases by 25% Maximum dose of 7 mg/kg is reached Increase in heart rate by 30 points Procainamide can be administered to suppress wide-complex tachycardias except in patients displaying hypotension, a QRS increase of 50%, or the maximum dose of 17 mg/kg is met. AHA Advanced Cardiovascular Life Support Provider Manual, p. 133, 168